Evidence map›Paper›PMID 42039853›Full record

ReviewInternational journal of nanomedicine2026

Concept of 2D van der Waals Nanohybrids for Key Biomedical Applications.

N Sanoj Rejinold, Jin-Ho Choy

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

N Sanoj RejinoldIntelligent Nanohybrid Materials Laboratory (INML), Department of Chemistry, College of Science and Technology, Dankook University, Cheonan, 31116, Republic of Korea.ORCID 0000-0002-7045-0563
Jin-Ho ChoyIntelligent Nanohybrid Materials Laboratory (INML), Department of Chemistry, College of Science and Technology, Dankook University, Cheonan, 31116, Republic of Korea.ORCID 0000-0002-4149-7100

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The past decade has witnessed a fundamental shift in 2D nanomaterials, from isolated single-component sheets to vdW nanohybrids, architected as stacked, stitched, or surface-engineered assemblies of chemically distinct layers. Enabled by weak interlayer forces, these hybrids permit modular integration of photonic, catalytic, electronic, and bioactive functions without lattice matching or harsh chemistries. In biomedicine, this modularity is transformative: one layer can absorb Near Infrared, NIR light for photothermal or photodynamic therapy, another can intercalate and release drugs or nucleic acids, a third can modulate redox biology through ROS scavenging or nanozyme activity, while polymeric or biomimetic coatings provide immune evasion, targeting, or biodegradability. Compared with isotropic nanoparticles, 2D vdW interfaces offer maximal surface area, multivalent binding, anisotropic ion/electron transport, tissue-compliant mechanics, and engineerable interlayer galleries for controlled, stimulus-responsive release. Crucially, vdW stacking preserves the intrinsic properties of each layer while enabling emergent synergistic behaviors including photothermal-photodynamic coupling, catalytic-photonic amplification, mechanobiology-driven responsiveness, and staged therapeutic logic. Together, these attributes position vdW nanohybrids as a powerful and versatile class of materials poised to redefine therapeutic, diagnostic, regenerative, and bioelectronic frontiers in next-generation nanomedicine.

Indexed as

NanomedicineNanostructuresAnimalsHumansPhotochemotherapy2D materialsbiomedical applicationslayered double hydroxidesLDHmxeneVan Der Waals nanohybrids

Identifiers

PMID42039853
PMCPMC13109988

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.